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Abstract 
Background: The utility of lymph node mapping to improve staging in colon cancer is still under evaluation. Laparoscopic colectomy for 
colon cancer has been validated in multi-centric trials. This study assessed the feasibility and technical aspects of lymph node mapping 
in laparoscopic colectomy for colon cancer. 
Methods: A total of 42 patients with histologically proven colon cancer were studied from January 2006 to September 2007. Exclusion 
criteria were: advanced disease (clinical stage III), rectal cancer, previous colon resection and contraindication to laparoscopy. Lymph-
nodal status was assessed preoperatively by computed tomography (CT) scan and intra-operatively with the aid of laparoscopic 
ultrasound. Before resection, 2–3 ml of Patent Blue V dye was injected sub-serosally around the tumour. Coloured lymph nodes were 
marked as sentinel (SN) with metal clips or suture and laparoscopic colectomy with lymphadenectomy completed as normal. In case of 
failure of the intra-operative procedure, an ex vivo SN biopsy was performed on the colectomy specimen after resection. 
Results: A total number of 904 lymph nodes were examined, with a median number of 22 lymph nodes harvested per patient. The SN 
detection rate was 100%, an ex vivo lymph node mapping was necessary in four patients. Eleven (26.2%) patients had lymph-nodal 
metastases and in five (45.5%) of these patients, SN was the only positive lymph node. There were two (18.2%) false-negative SN. In 
three cases (7.1%) with aberrant lymphatic drainage, lymphadenectomy was extended. The accuracy of SN mapping was 95.2% and 
negative predictive value was 93.9%. 
Conclusions: Laparoscopic lymphatic mapping and SN removal is feasible in laparoscopic colectomy for colon cancer. The ex vivo 
technique is useful as a salvage technique in case of failure of the intra-operative procedure. Prospective studies are justified to 
determine the real accuracy and false-negative rate of the technique. 
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Context 
The metastatic status of regional lymph nodes is a major 
prognostic factor in colon cancer and is particularly important for 
determining adjuvant therapy [1–4]. Five-year survival is 85–
95% for stage I colon cancers, 60–80% for stage II, but 30–60% 
for stage III disease (characterized by nodal involvement) [5, 6]. 
Adjuvant chemotherapy confers a 33% survival benefit in 
patients with stage III disease [7, 8], but serves no purpose in 
patients without nodal involvement [9]. However, survival 
variability and high recurrence rates in stage II patients suggest 
that current lymph node staging procedures understage too 
many patients. 
Key variables determining whether lymph node metastases are 
found (and what stage is assigned) are the number of nodes 
harvested [2, 3] and the method of node evaluation [4]. The 
probability of finding an involved node increases with number of 
nodes recovered, suggesting that all palpable nodes, even 
small ones, should be harvested [2]. Similarly, the conventional 
node examination method—single-level sectioning and 
haematoxylin and eosin (H&E) staining—may fail to detect 
tumour cells [4]. At the same time methods of lymph node 
ultrastaging, such as multi-level sectioning, immuno-
histochemistry and polymerase chain reaction, are costly and 
time-consuming particularly if applied to all nodes harvested. 
Sentinel lymph node (SN) mapping, developed to identify and 
examine the nodes at highest risk of metastatic involvement in 
patients with melanoma and breast cancer [10, 11], has been 
shown to improve staging in these diseases. The aims of SN 
mapping in colon cancer are to identify and examine the nodes 
with highest probability of metastatic involvement, and also to 
identify nodes not on conventional lymphatic tracts. 
Laparoscopic surgery is a validated method for the treatment of 
colon cancer [12–14]; however, few publications have described 
SN mapping in laparoscopic colon resection [15–20]. The 
purpose of this paper is to describe technical aspects of SN 
mapping in laparoscopic colon surgery for colon cancer, and to 
assess its feasibility in an initial series of patients. 
 
Materials and Methods 
Patients 
From January 2006 to September 2007 44 patients—26 men, 
18 women, mean age 63 years (range 31–74) with clinical
stages I and II colon cancer—were prospectively enrolled in the 
study. Exclusion criteria were metastatic disease, rectal cancer, 
advanced disease with invasion of adjacent structures, previous 
colonic resection and contraindications to laparoscopy. Five 
earlier cases, not included in the series, were used to gain 
experience with SN mapping. Exclusion criteria were metastatic 
disease, rectal cancer, advanced disease with invasion of 
adjacent structures, previous colonic resection and 
contraindications to laparoscopy. 
Pre-operative work-up comprised abdominal and pelvic CT, 
chest x-ray and colonoscopy with biopsy. Lymph-nodal clinical 
stage was assessed preoperatively by CT scan and intra-
operatively by a complete laparoscopic staging with 
laparoscopic ultrasound. 
Lymph nodes detected by CT scan with a volume higher than 
1.0 cm were considered positive. Patients with distant 
metastases, T4 disease or clinical-node-positive disease 
discovered during intra-operative staging were excluded (two 
patients of the present series). The lesion, identified during 
colonoscopy, was marked with china ink or metal clips for 
subsequent laparoscopic identification. The positions of any 
polyps removed during colonoscopy were also marked [21]. 
Technique 
All lymph node mapping procedures were performed by a single 
surgeon (PPB), experienced in SN detection. After pneumo-
peritoneal insufflation to about 12 mmHg, complete 
laparoscopic disease staging was performed with the aid of 
laparoscopic ultrasonography [22]. After lesion location, 
insufflation pressure was reduced to 6 mmHg, the colonic 
segment containing the lesion was carefully manoeuvred to the 
abdominal wall with the aid of atraumatic graspers, and the site 
of percutaneous access was selected. Colon mobilization was 
not performed at this stage in order to maintain lymphatic tree 
integrity. 
A 22-gauge spinal needle was inserted into the colon sub-
serosally at an angle of about 45° to the tangential plane of the 
colon at the chosen injection site. Low insufflation pressure 
helped obtain the correct needle insertion angle. Care was 
taken to avoid inserting the needle too far (into the muscular 
layer). Patent Blue V dye (SALF, Bergamo, Italy) 2–3 ml was 
injected sub-serosally at 3–4 sites around the tumour. A large 
sponge was inserted into the abdominal cavity and positioned 
close to the needle, to mop up any dye leakage. 
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To view this video click here: 
 
http://www.ecancermedicalscience.com/view-article.asp?doi=10.3332/ecancer.2008.60
Five to ten minutes were usually necessary to visualize the 
lymph ducts and the first node to receive dye. In obese patients, 
the mesenteric peritoneum was gently dissected to reveal the 
lymphatic path to a lymph node. The first lymph nodes to take 
up dye were considered SNs and marked with metal clips or a 
suture. 
Care was taken to identify any coloured lymph nodes at unusual 
sites that would indicate the lymphadenectomy should be 
extended, as in a patient with a cancer of the right colon, where 
a blue lymph node was identified at the root of the transverse 
meso-colon. 
Insufflation pressure was increased to 12 mmHg and the 
colectomy was completed with ligation of the mesenteric blood 
vessels at their origins and radical lymphadenectomy. In left 
colon resections, a medial-to-lateral technique was used, with 
complete splenic flexure mobilization and intra-corporeal 
transanal double-stapled anastomosis. For right colon resection, 
the anastomosis was performed extra-corporeally, via median 
periumbilical mini-laparotomy. 
In four cases, ex vivo SN mapping was performed on the 
colectomy specimen immediately after resection, following the 
failure of intra-corporeal mapping. The procedure was similar to 
that used for intra-corporeal SN mapping. In all cases, marked 
SNs were removed from the resected specimen and sent to the 
pathologist separately. 
 
Results 
In two of the 44 patients enrolled, SN mapping was not 
performed because the unexpected detection at the intra-
operative staging of advanced disease. Thus SN mapping was
successfully performed in 42 patients, 17 of whom had right 
colon and 25 had left colon lesions. The mean duration of the 
mapping procedure was 14 minutes (range 10–18). 
Eight patients received pre-laparoscopic endoscopic 
polypectomy and the resections site(s) were marked with black 
ink. In seven patients, the lesions identified endoscopically were 
tagged with two metal clips, permitting the use of ultrasound for 
intra-operative tumour localization. 
Ex vivo procedure was performed in four cases because of 
failure of intra-operative mapping. In all the cases, the cause of 
failure was due to technical difficulties, with spillage of the dye 
inside the lumen of the colon in one case and in another in the 
peritoneal cavity; in another patient, with a lesion located in the 
left colon, the left meso-colon and mesentery adhered together 
and it was not possible to complete the SN mapping; and in the 
last case, an obese patient with a body mass index of 49, with a 
small lesion of the right colon, the exact site of the lesion was 
not evident intra-operatively. 
At least one SN was identified intra-corporeally in 38 patients. In 
the remaining cases, after the specimen had been removed, ex 
vivo mapping was performed successfully. A total of 904 lymph 
nodes were harvested with a median of 22 (range 8-–38) lymph 
nodes per patient. SNs identified were 93, an average of two 
(range 1–4) per patient. Eleven (26.2%) patients had positive 
lymph nodes and positive SNs were found in nine patients 
(21.4%). Thus, in two cases, the SNs were negative and non-
SNs were positive, the false-negative rate was therefore 2/11 = 
18.2% (Table 1). In five cases, the SN was the only positive 
node (possible upstage) and in 40 cases (95.2%) the SN 
correctly reflected nodal status. Isolated tumour cells were 
found in the SNs of two patients and cytokeratin 
immunohistochemistry was necessary to confirm metastasis.
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Table 1: Results of sentinel node mapping in 42 patients undergoing laparoscopic colectomy for colon cancer 
 
Table 2: Pathological staging of 42 patients undergoing laparoscopic colectomy for colon cancer 
 
Micro-metastasis was found in one SN. Thus three patients 
(9.6%) were truly upstaged by ultrastaging methods. The 
pathological staging of all patients is shown in Table 2. 
In three (7.1%) patients, mapping revealed lymphatic drainage 
outside the planned margins of the resection. Two cases were 
right colon cancer, in one SN mapping revealed a blue node at 
the base of the transverse meso-colon, to the left of the middle 
colic artery, in the other, an SN was located near the small 
bowel wall at more than 10 cm from the ileocecal valve and in 
the third patient, with a left colon lesion, a blue node was 
revealed in the aortic bifurcation plane. In all these cases, the 
lymphadenectomy was extended to include the blue nodes. In 
all cases, SNs were negative at histopathologic examination, 
and disease stage did not change. 
 
Discussion 
The main goal of SN mapping in colon cancer is to improve 
lymph-nodal staging to identify the number of patients classified 
as stage II, and varying from 20% to 30%, that will die within 
five years from tumour relapse or distant metastases and will 
thus benefit from adjuvant chemotherapy [4–6]. Furthermore, 
patients with advanced diseases will receive adjuvant 
chemotherapy anyway. Therefore the study of SNs should be 
directed only to these early stages. 
Moreover an accurate selection of patients, excluding advanced 
diseases, would reduce the number of skip metastases and 
would increase the detection rate of SN mapping. In fact, in 
advanced diseases lymphatic flow may be altered by the 
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closure of lymphatic ducts near the lesion. Therefore we 
decided to concentrate our SN study only on patients with a 
clinical stage I or II disease. These early stage patients are the 
class of patients that can benefit more from minimally invasive 
treatment, because the highest number of conversions from 
laparoscopy to laparotomy are in advanced cancer cases, with 
invasion of the adjacent structure and in the bulky diseases 
[23]. 
Few publications have described SN mapping in laparoscopic 
colon resection [15–20]. In all the studies, as in ours, lymphatic 
mapping was performed with blue dye injected sub-serosally, 
intra-operatively or sub-mucosally by intra-operative endoscopy. 
This is a quick (mean duration 14 minutes) and quite easy 
method. When technical difficulties are present and SN 
mapping fails, the ex vivo mapping is performed as a salvage 
technique. Some authors have performed only this ex vivo 
technique [24, 25], but in our opinion in vivo mapping has a 
relevant role. This is because it detects aberrant lymphatic 
drainage (7.1% in this series), avoids the interruption of the 
lymphatic pathway by any surgical manipulation, and because 
the direct visualization of lymphatic pathway, particularly in 
laparoscopic surgery, gives a clearer identification of the lymph 
nodes basin, helping the surgeon execute a radical 
lymphadenectomy. 
Since 1999 numerous papers on the SN technique in colorectal 
cancer have been published, with a wide range of results in 
terms of accuracy and false negatives: False-negative rates in 
fact vary from 0% to 60% [26–36]. This astonishing range has 
several explanations. First the SN mapping technique has not 
been standardized; some authors inject blue dye sub-mucosally 
via an endoscopic approach; others prefer intra-operative sub-
serosal injection; others again use radioactive tracer either 
injected sub-mucosally the day before surgery, or sub-serosally 
intra-operatively [37–39]. Use of fluorescein dye has been 
described with good results [40], and recently, an intra-operative 
near-infrared fluorescence imaging system has been reported 
that displays surgical anatomy and injected quantum dots by 
near-infrared fluorescence [41]. 
Saha et al [36] emphasized the importance of adequate training 
and use of a standardized technique to reduce technical 
problems, and this matches our own experience. We emphasize 
also that an adequate amount of dye, injected at 3–4 points 
around the tumour, is crucial for success. At the same time 
intra-luminal dye leakage must be avoided to prevent dye 
absorption (and subsequent diffusion) by areas distant from the 
primary. Viehl et al [42] also emphasized these points, noting 
that the injection of 1 ml of dye is insufficient to reliably identify 
SNs. We use 2–3 ml, and tend to use more in patients with a 
thick meso-colon. 
Patient selection may influence the success rate of SN mapping 
and staging accuracy; large cancers and those with massive 
nodal involvement are likely to alter lymphatic flow by closing 
lymphatic ducts near the lesion and hence increase the false-
negative rate. Furthermore, in advanced disease, SN study is 
less useful as patients will receive adjuvant chemotherapy 
anyway. In a recent multi-centric trial, a cut-off level of 22 
patients was defined to increase detection rate from 76.4% to 
91.0% [43]. 
A more intriguing problem is the prognostic significance of 
micro-metastases and isolated tumour cells (ITCs) in the SN. 
Some studies have found that patients with a clear SN have 
better survival than those with micro-metastases [44, 45]; other 
studies indicate that micro-metastases and ITCs have no 
prognostic significance [35, 46]. 
The prognostic implications of SN mapping for nodal staging 
and recurrence emerged clearly from the multi-centre SN 
mapping trial of Saha et al [36]. Among patients with a minimum 
of two years' follow-up, they found a seven per cent recurrence 
rate in those undergoing SN mapping compared to a 25% 
recurrence rate in those receiving standard resection and nodal 
staging. Furthermore, among the 500 patients receiving SN 
mapping, metastases were detected in 50%, while among the 
368 patients not mapped, nodal metastases were detected in 
only 35%. However, the Saha et al trial employed open surgery. 
The experience of this study is that SN mapping is feasible, as it 
is a relatively brief procedure and identified at least one SN in 
all 42 cases. The achievement of this good result depended on 
the employment of standardized procedures learnt by 
experience, including reduction of intra-abdominal pressure 
during injection, injecting sub-serosally at an angle of about 45°, 
and mopping up any dye leakage with a large sponge. In our 
series, SN status reflected regional node status in 40 out of 42 
cases giving an accuracy of 95.2%. 
We harvested a median of 22 lymph nodes per patient; further 
indication that laparoscopic colectomy provides an oncologically 
adequate approach. In two patients (7.1%), the 
lymphadenectomy was extended to nodal stations not usually 
included in the resection, following identification of SNs outside 
the margins of the initially planned resection. Somewhat higher 
(29% and 28%) proportions of aberrant lymph drainage were 
reported by Tsioulias et al [16] and Bilchik and Trocha [18], 
while in both these studies less lymph nodes per patient were 
harvested. 
 5  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2007, 1:60 
 
The false-negative rate of 18.2% is the least satisfactory finding 
of our study; nevertheless, it is not of huge relevance, because 
these patients have been correctly staged, and have received 
adjuvant chemotherapy anyway. 
Our overall experience in this study indicates that SN mapping 
in laparoscopic colectomy is feasible, with a high accuracy rate, 
and promising as a method of improving the nodal staging of 
stages I and II colon cancer. Larger prospective studies to 
determine the accuracy and false-negative rate of the technique 
as well as the prognostic role of micro-metastasis and ITC are 
justified. 
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